Interleukin News and Research

RSS

New framework maps the complex link between psychological status and cardiovascular health

CVD remains the leading cause of death worldwide, while the global burden of mental disorders continues to rise.

28 Sep 2026

Emerging therapies expand the treatment landscape for coronary artery disease

Announcing a new article publication for Cardiovascular Innovations and Applications. Coronary artery disease (CAD) remains the leading cause of death globally, despite the limited efficacy of current pharmacological therapies.

25 Sep 2026

Specialized immune cells bridge the nervous and immune systems

A collaborative team led by Professor Jie Zhou at Tianjin Medical University School of Basic Medicine and Professor Qiang Liu at Tianjin Medical University General Hospital published a comprehensive review in Volume 2 of the journal Immunity & Inflammation on September 8, 2026.

25 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

New study highlights difficulty of detecting gastric ulcer pain in horses

A new study led by Australian veterinarians has exposed the challenge of identifying pain in horses with gastric ulcers and highlights an urgent need to better detect when horses are suffering.

23 Sep 2026

Cancer-related DNA changes may appear in blood years before diagnosis

Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular signatures associated with future prostate and breast cancer, with prostate silencer methylation providing the stronger risk stratification. Breast enhancer signals were weaker and varied by subtype and disease stage, indicating that cfDNA methylation may have greater value for risk assessment and surveillance than as a standalone diagnostic test.

23 Sep 2026

What links smoking, body fat, mental health, genes, and heart risk? Inflammation may be part of the answer

In a large UK Biobank study, higher levels of the chronic inflammation marker GlycA were associated with smaller heart chambers, thicker heart walls, impaired diastolic function, reduced stroke volume, and a 43% higher risk of major adverse cardiovascular events in the highest versus lowest GlycA group. Genetic susceptibility also modified the associations between environmental exposures, inflammation, and cardiovascular risk, while inflammatory proteins in the IL-1, TNF, and IL-6 pathways statistically mediated several of these associations.

23 Sep 2026

Regular exercisers show distinct metabolic and immune signatures in blood

Researchers compared blood samples from 40 regular exercisers and 46 sedentary adults and found differences in metabolites, blood chemistry, and immune cell gene activity. The patterns suggested greater fatty acid use and altered immune signaling among exercisers, but the study could not establish that exercise caused these differences.

21 Sep 2026

Chronic stress and inflammation cause silent structural heart damage

Chronic stress from people's everyday lives may be causing lasting structural changes to the heart, harming health and reducing life expectancy.

18 Sep 2026

Shatavari may affect more than hormones, and the gut could help explain why

A review in Nutrients examined how bioactive compounds in Asparagus racemosus (Shatavari) may influence cognitive health through the microbiota-gut-brain axis, estrogen-related signaling, neuroinflammation, oxidative stress, and neurotransmitter regulation. Evidence from computational, cellular, animal, and limited human studies suggests several plausible biological pathways, but key questions remain about bioavailability, brain exposure, dosing, and clinical efficacy.

16 Sep 2026

Scientists tested how much whole grain makes a difference. The answer was not simply “more”

A meta-analysis of 87 randomized trials found that increasing whole-grain intake was associated with improvements in several cardiometabolic risk factors, although many individual changes were small or clinically unimportant. Dose-response analyses suggested that the magnitude of the effects varied by outcome and intake level, with limited evidence at very high intakes.

16 Sep 2026

Eating four to six wholegrain servings daily protects heart health

Eating four to six servings of wholegrain each day reduces several major risk factors for cardiovascular disease, according to a new study published in the European Heart Journal today (Wednesday).

16 Sep 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

Refined starch activates immune pathways after low-carb weight loss

After substantial weight loss on a very-low-carbohydrate diet, participants who switched to a diet rich in refined starch showed greater activation of circulating immune and metabolic pathways than those who continued the low-carbohydrate diet or consumed a high-carbohydrate diet rich in added sugar. Mouse experiments suggested that activation of the complement immune pathway may help explain the inflammatory response associated with starch intake.

10 Sep 2026

Gut microbiome may reveal inflammation and future disease risk better than age

Gut microbiota composition explained more variation than chronological age in nearly all inflammatory cytokines and most physiological measures examined, with specific microbial profiles linked to markedly different patterns of inflammation across adulthood. People with the Bacteroides 2 enterotype showed an inflammaging-like profile decades earlier than other groups and had a higher risk of subsequent disease, while a high-diversity microbiota profile was associated with lower inflammation and reduced disease incidence.

9 Sep 2026

New biologic therapy significantly reduces COPD flare-ups in trials

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

8 Sep 2026

Vitamin A derivative prevents immune cell exhaustion in brain tumors

Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells.

8 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

What your gut microbes may have to do with how your brain ages

This review examines how diet-driven changes in the gut microbiota and microbial metabolites may influence cognitive aging through immune, metabolic, neural, endocrine, and barrier-related pathways. It highlights SCFAs, tryptophan-derived metabolites, and bile acids as key signaling mediators while emphasizing that much of the mechanistic evidence remains preclinical and human evidence is largely associative.

3 Sep 2026